Are you ready to offer REBYOTA to your appropriate patients?
Download these resources to help you set up protocols, an EHR order set, or refer a patient.
OPERATIONAL SET-UP TOOLKIT
Click the thumbnails or buttons below to download helpful REBYOTA resources.
Protocol Documents
Protocol Documents
Download these forms to help you prep for pre- and post-REBYOTA administration.
These protocol documents clearly lay out
all steps ranging from patient referral,
patient benefits verification, ordering and
storage of REBYOTA, and administration
best practices.
Order Set Guides
Download the appropriate EPIC or CERNER guide to assist in efficiently implementing an electronic health record (EHR) into your site of care to help facilitate the REBYOTA ordering process.
REBYOTA PATIENT REFERRAL PROGRAM FORM
If you would like your patient to receive REBYOTA from a participating administration site, please download this form to get them started.
If you would like your patient to receive REBYOTA from a participating administration site, please download this form to get them started.
IMPORTANT SAFETY INFORMATION
INDICATION
REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.
Limitation of Use
REBYOTA is not indicated for treatment of CDI.
IMPORTANT SAFETY INFORMATION
Contraindications
Do not administer REBYOTA to individuals with a history of a severe allergic reaction (eg, anaphylaxis) to any of the known product components.
Warnings and Precautions
Transmissible infectious agents
Because REBYOTA is manufactured from human fecal matter, it may carry a risk of transmitting infectious agents. Any infection suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Ferring Pharmaceuticals Inc.
Management of acute allergic reactions
Appropriate medical treatment must be immediately available in the event an acute anaphylactic reaction occurs following administration of REBYOTA.
Potential presence of food allergens
REBYOTA is manufactured from human fecal material and may contain food allergens. The potential for REBYOTA to cause adverse reactions due to food allergens is unknown.
Adverse Reactions
The most commonly reported (≥3%) adverse reactions occurring in adults following a single dose of REBYOTA were abdominal pain (8.9%), diarrhea (7.2%), abdominal distention (3.9%), flatulence (3.3%), and nausea (3.3%).
Use in Specific Populations
Pediatric Use
Safety and efficacy of REBYOTA in patients below 18 years of age have not been established.
Geriatric Use
Of the 978 adults who received REBYOTA, 48.8% were 65 years of age and over (n=477), and 25.7% were 75 years of age and over (n=251). Data from clinical studies of REBYOTA are not sufficient to determine if adults 65 years of age and older respond differently than younger adults.
You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call
1-800-332-1088.
Please click here for full Prescribing Information.